Eli Lilly said Monday that its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity, according to results from a late-stage trial. The company plans to file with the U.S. Food and Drug Administration by the end of the year for approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults who have obesity or are overweight.
The pill rolled out in the U.S. in April.
In one study of 363 patients who could not or would not use positive airway pressure (PAP) therapy, patients taking Foundayo had an average of 21.1 fewer apnea-hypopnea index (AHI) events per hour at 52 weeks. Patients on placebo averaged a reduction of 4.8 per hour. Lilly said Foundayo produced an overall AHI reduction of 43.8%, compared with 6.3% for placebo, and that 31.5% of participants in the Foundayo group met criteria for remission or improvement to mild sleep apnea.
In a second study of 349 patients already using PAP therapy, Foundayo produced an overall AHI reduction of about 27.5%, compared with 3% for placebo. Lilly said 19.6% of those participants met criteria for remission or mild sleep apnea.
Lilly also reported that patients lost roughly 11% of their weight across groups at 52 weeks. About 12% of patients not using PAP therapy on Foundayo stopped the drug because of side effects, compared with 3.8% on placebo. Among patients using both Foundayo and PAP, 6.8% discontinued due to side effects, compared with 0.6% on placebo. The most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, which Lilly described as generally mild to moderate.
Lilly said Zepbound became the first medication approved in the U.S. for sleep apnea in December 2024.